Pooja Bhat

Dr. Pooja Bhat

Department of Ophthalmology, University of Illinois College of Medicine, Chicago, IL 60612, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2019 in Advances in Ophthalmology and Optometry
Verified
Journal Article
Closed access
JCJudy L. Chen
Judy L. Chen
PBPooja Bhat
Pooja Bhat
ALAnn-Marie Lobo
Ann-Marie Lobo

7 April 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
DODaniel J. Oh
Daniel J. Oh
ASArjun Singh
Arjun Singh
LKLevi N. Kanu
Levi N. Kanu
ALAnn-Marie Lobo-Chan
Ann-Marie Lobo-Chan
PMPeter W MacIntosh
Peter W MacIntosh
PBPooja Bhat
Pooja Bhat
Purpose: To evaluate the utility and side effect profile of subcutaneous repository corticotropin gel (RCI) in ocular sarcoidosis. Methods: Retrospective chart review. Results: Among six identified patients on RCI therapy, 4 had uveitis, one had optic neuritis and one had uveitis and optic neuritis secondary to sarcoidosis. The average follow-up was 43.5 months. RCI therapy was continuous in 4 patients (average 7.7 months) and intermittent in 2 patients (24 and 12 months). Five of the 6 patients continued with local and/or systemic corticosteroids for ocular inflammation control while on RCI therapy. Two-thirds of patients experienced adverse effects including hyperpigmentation, alopecia, and severe hypertension. RCI therapy was discontinued in 5 of the 6 patients due to continued inflammation and side/adverse effects (4 patients) and loss of follow-up (1 patient). Conclusion: In this small cohort, the majority of patients failed to achieve adequate steroid-sparing ocular inflammation control and experienced side effects while on RCI therapy. Additional studies are needed to elucidate the role of RCI in ocular inflammation.

9 July 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
ALAnn-Marie Lobo-Chan
Ann-Marie Lobo-Chan
PMPeter MacIntosh
Peter MacIntosh
PBPooja Bhat
Pooja Bhat
Repository corticotropin injection (RCI) has recently gained attention in the field of ocular inflammatory disease. Data supporting the use of RCI therapy in ocular inflammation are limited to case reports or small series subject to publication bias toward positive results. How this therapy differs significantly from oral corticosteroids, which are significantly cheaper, is unknown. Clinical trials to investigate the efficacy of RCI are currently limited to open-labeled non-comparative studies. Side effects of RCI are not insignificant, have been reported in other fields of medicine, and require further scrutiny. Finally, the price of RCI has skyrocketed with average yearly cost of therapy estimated to be between $480,000-$850,000 with allegations of the RCI manufacturing drug company providing remuneration to induce healthcare providers to prescribe RCIs but without any repercussions from a regulatory standpoint. The significant cost of RCI combined with lack of evidence-based guidance on efficacy, safety, and indications for use in ocular inflammation warrant caution in utilizing this therapy.

29 May 2019
Verified
Book Chapter
Open access
PDF file
JCJudy L. Chen
Judy L. Chen
ALAnn-Marie Lobo
Ann-Marie Lobo
RCRobison Vernon Paul Chan
Robison Vernon Paul Chan
PBPooja Bhat
Pooja Bhat
Biologic agents represent a mainstay in the treatment of refractory non-infectious, immune-mediated uveitis. Tumor necrosis factor (TNF)-α inhibitors have demonstrated efficacy in inducing and sustaining disease remission in numerous systemic inflammatory disorders and their associated uveitic entities. In particular, studies have shown that infliximab and adalimumab can induce steroid-free disease remission in patients with Behçet’s disease and juvenile arthritis as treatments that are superior to conventional disease-modifying immunosuppressive agents. Patients receiving anti-TNF-α therapy may experience adverse events and should be closely monitored for the development of opportunistic infections, reactivation of tuberculosis and hepatitis, demyelinating disease and neuropathies, as well as malignancies.

3 January 2017 in Expert Review of Ophthalmology
Verified
Journal Article
Closed access
MZMei P. Zhou
Mei P. Zhou
PBPooja Bhat
Pooja Bhat
Introduction: Serpiginous choroiditis is a rare posterior uveitis with characteristic posterior segment findings of choroiditis in a serpiginous-like fashion. Typically the disease extends from the optic nerve in the acute phase and leave behind areas of RPE and choriocapillaris atrophy. The clinical characteristics are well described but the etiology remains unknown and treatment is challenging. Areas covered: This review aims to update the clinician with an analysis of recent research on clinical outcomes as well as treatment options. Characteristic clinical findings are reviewed as well as findings on traditional (fluorescein angiography) and newer imaging modalities such as optical coherence tomography angiography (OCTA). The paper also reviews recent data on treatment options to slow disease progression and improve visual acuity outcomes. Expert commentary: This review highlights the gaps in our understanding of disease pathogenesis and discusses the results of clinical studies on treatment modalities. We emphasize the need to distinguish tuberculous serpiginous-like choroidopathy. Advancements in imaging modalities holds promise to further our understanding of the disease process as well as help to monitor response to treatment.

4 December 2020
Verified
Book Chapter
Closed access
PDF file
RSRavand Samaeekia
Ravand Samaeekia
PBPooja Bhat
Pooja Bhat